Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

A Prognostic Gene Signature for Metastasis-Free Survival of Triple Negative Breast Cancer Patients

Figure 8

The BPMS is prognostic for high risk patients among the clinically predicted poor outcome and high recurrence patients.

Clinically relevant gene signatures (A) Mammaprint® Poor (23 BPMS+ patients out of 226 Mammaprint Poor patients, χ2 = 4.3) and (B) OncotypeDX® Recurrence High (16 BPMS+ patients out of 257 RS High patients, χ2 = 6.7) were stratified for MFS using the BPMS. Red indicates patient tumors that express the BPMS signature while black indicates patient tumors that do not. Survival curves were generated by Kaplan–Meier analysis, and the indicated P-values were calculated by the log-rank test.

Figure 8